These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 17692447)

  • 41. The assessment of drugs in obsessional states.
    Philpott R
    Br J Clin Pharmacol; 1976 Feb; 3(1 Suppl 1):91-5. PubMed ID: 973952
    [No Abstract]   [Full Text] [Related]  

  • 42. Delusional disorder, somatic type treated with aripiprazole--mirtazapine combination.
    Dimopoulos NP; Mitsonis CI; Psarra VV
    J Psychopharmacol; 2008 Sep; 22(7):812-4. PubMed ID: 18308798
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Ziprasidone as coadjuvant treatment in resistant obsessive-compulsive disorder treatment].
    Iglesias Garcia C; Santamarina Montila S; Alonso Villa MJ
    Actas Esp Psiquiatr; 2006; 34(4):277-9. PubMed ID: 16823689
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Aripiprazole in a therapy-resistant patient with borderline personality and post-traumatic stress disorder.
    Kellner M
    Pharmacopsychiatry; 2007 Jan; 40(1):41. PubMed ID: 17327963
    [No Abstract]   [Full Text] [Related]  

  • 45. Combined lithium-tricyclic treatment of obsessive-compulsive disorder.
    Golden RN; Morris JE; Sack DA
    Biol Psychiatry; 1988 Jan; 23(2):181-5. PubMed ID: 3334887
    [No Abstract]   [Full Text] [Related]  

  • 46. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
    Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
    J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder.
    Pigott TA; Pato MT; L'Heureux F; Hill JL; Grover GN; Bernstein SE; Murphy DL
    J Clin Psychopharmacol; 1991 Aug; 11(4):242-8. PubMed ID: 1918422
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Amantadine augmentation for refractory obsessive-compulsive disorder: a case report.
    Pasquini M; Berardelli I; Biondi M
    J Clin Psychopharmacol; 2010 Feb; 30(1):85-6. PubMed ID: 20075660
    [No Abstract]   [Full Text] [Related]  

  • 49. Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients.
    Greist JH; Jefferson JW; Rosenfeld R; Gutzmann LD; March JS; Barklage NE
    J Clin Psychiatry; 1990 Jul; 51(7):292-7. PubMed ID: 2195006
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What is the optimal approach to the pharmacological management of obsessive-compulsive disorder?
    Ravindran AV
    J Psychiatry Neurosci; 1998 Mar; 23(2):136. PubMed ID: 9549253
    [No Abstract]   [Full Text] [Related]  

  • 51. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder.
    Pato MT; Pigott TA; Hill JL; Grover GN; Bernstein S; Murphy DL
    Am J Psychiatry; 1991 Jan; 148(1):127-9. PubMed ID: 1984696
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder.
    Masi G; Pfanner C; Millepiedi S; Berloffa S
    J Clin Psychopharmacol; 2010 Dec; 30(6):688-93. PubMed ID: 21105283
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pregnancy complicated by obsessive-compulsive disorder.
    Chelmow D; Halfin VP
    J Matern Fetal Med; 1997; 6(1):31-4. PubMed ID: 9029382
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clomipramine-induced tourettism in obsessive-compulsive disorder: clinical and theoretical implications.
    Moshe K; Iulian I; Seth K; Eli L; Joseph Z
    Clin Neuropharmacol; 1994 Aug; 17(4):338-43. PubMed ID: 9316681
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder.
    Yoshimura R; Kishi T; Hori H; Ikenouchi-Sugita A; Katsuki A; Umene-Nakano W; Iwata N; Nakamura J
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):355-7. PubMed ID: 22813840
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of obsessive-compulsive disorder using clomipramine in a very old patient.
    Trappler B
    Ann Pharmacother; 1999 Jun; 33(6):686-90. PubMed ID: 10410180
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aripiprazole augmentation for treatment-resistant bipolar depression: sustained remission after 36 months.
    Kemp DE; Dago PL; Straus JL; Fleck J; Karaffa M; Gilmer WS
    J Clin Psychopharmacol; 2007 Jun; 27(3):304-5. PubMed ID: 17502781
    [No Abstract]   [Full Text] [Related]  

  • 58. [The role of drug therapy in the treatment of obsessive-compulsive disorders].
    Teeuwisse JM; Nolen WA
    Ned Tijdschr Geneeskd; 1989 Dec; 133(52):2605-8. PubMed ID: 2575230
    [No Abstract]   [Full Text] [Related]  

  • 59. Aripiprazole augmentation of tranylcypromine in treatment-resistant major depression.
    Goforth HW; Carroll BT
    J Clin Psychopharmacol; 2007 Apr; 27(2):216-7. PubMed ID: 17414252
    [No Abstract]   [Full Text] [Related]  

  • 60. Management of clozapine-induced obsessive-compulsive symptoms in a man with schizophrenia.
    Zink M; Knopf U; Kuwilsky A
    Aust N Z J Psychiatry; 2007 Mar; 41(3):293-4. PubMed ID: 17464712
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.